Barclays lowered the firm’s price target on Jazz Pharmaceuticals to $200 from $230 and keeps an Overweight rating on the shares post the Q1 report. While the guidance was reaffirmed, the stock is unlikely to rerate on on the quarter and needs multiple pipeline catalysts to play out, including Zani, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
- Jazz Pharmaceuticals sees 2024 non-GAAP EPS $18.15-$19.35, consensus $18.93
- Jazz Pharmaceuticals reports Q1 non-GAAP EPS $2.68, consensus $4.18
- Baird starts Praxis Precision at Outperform on ulixacaltamide’s potential
- JAZZ Earnings this Week: How Will it Perform?